Quantcast

Latest gene delivery Stories

2014-08-14 16:26:36

GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ -- Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD. In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been...

2014-08-14 16:26:34

BERGISCH GLADBACH, Germany, August 14, 2014 /PRNewswire/ -- Addition of lentiviral gene delivery capabilities complements strategic partnering portfolio. Miltenyi Biotec announced today that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications. The acquisition further strengthens Miltenyi Biotec's portfolio in cell and...

2014-08-11 16:28:00

Oncothyreon to Leverage Alpine's Protocell Technology to Enable Targeted Delivery of Molecular Therapeutics for Serious Diseases Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately...

2014-07-15 08:28:34

Potential in Life Science Research Validates Newly Acquired Technology Platforms for the Delivery of Plasmid DNA and a Variety of RNA in Mammalian Cells LAWRENCEVILLE, N.J., July 15, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced initiation of sales of its proprietary reagent products for life science research. Celsion's reagent products are based on its newly acquired proprietary delivery platform technologies,...

2014-07-11 08:25:10

DUBLIN, July 11, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "International Transfection Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Transfection is a technique used to introduce nucleic acids (either DNA or RNA) into cells. This technology helps the cells to regulate gene therapy, mutation of cancer cells and protein metabolism by...

2014-07-07 12:28:59

Engineered Cells Known As CTL019 Are the First Therapy of Their Kind to Obtain Designation PHILADELPHIA, July 7, 2014 /PRNewswire/ -- A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The investigational therapy, known as CTL019, is the first personalized cellular therapy for the...

2014-06-28 12:53:00

Texas A&M AgriLife Communications Scientists with Texas A&M AgriLife Research have found a "Trojan horse" way to deliver proteins into live human cells without damaging them. The finding, published in this month's Nature Methods, is expected to be easily adopted for use in medical research to find cures and treatments for a wide range of diseases, according to the team's lead scientist, Dr. Jean-Philippe Pellois, an associate professor of biochemistry at Texas A&M...

2014-06-19 08:28:26

RICHMOND, Calif., June 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's Board of Directors. Ms. Parker, who founded and served as President and CEO of Targeted Genetics Corporation, brings more than 30 years of experience in the biotechnology industry, including 16 years of specific experience in cell and gene therapy. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO "We are very pleased to...

2014-06-16 08:29:08

Company will draw on leaders' expertise in rare diseases, R&D and commercialization as it moves to complete development of its lead program in inherited blindness PHILADELPHIA, June 16, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today the appointments of Lars Ekman, former president of research and development at Elan, and Vin Milano, former president and CEO of...

2014-06-10 13:27:17

Duke University Ubiquitous protein controls copying of resistant DNA Staph infections that become resistant to multiple antibiotics don't happen because the bacteria themselves adapt to the drugs, but because of a kind of genetic parasite they carry called a plasmid that helps its host survive the antibiotics. Plasmids are rings of bare DNA containing a handful of genes that are essentially freeloaders, borrowing most of what they need to live from their bacterial host. The plasmids...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related